Martin Krakauer

List of Publications by Year
in descending order

44 papers	1,338 citations	361413 20 h-index	345221 36 g-index
49 all docs	49 docs citations	49 times ranked	2289 citing authors

#	Article	IF	Citations
1	Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology, 2009, 73, 2003-2010.	1.1	193
2	T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology, 2008, 125, 161-169.	4.4	175
3	Differential microRNA expression in blood in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1849-1857.	3.0	110
4	Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. Journal of Neuroinflammation, 2012, 9, 215.	7.2	66
5	Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-Î² treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Multiple Sclerosis Journal, 2008, 14, 622-630.	3.0	64
6	A Prospective Comparative Study of Parathyroid Dual-Phase Scintigraphy, Dual-Isotope Subtraction Scintigraphy, 4D-CT, and Ultrasonography in Primary Hyperparathyroidism. Clinical Nuclear Medicine, 2016, 41, 93-100.	1.3	57
7	CD4+ memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. Journal of Neuroimmunology, 2006, 181, 157-164.	2.3	51
8	Effect of High-Dose vs Standard-Dose Vitamin D Supplementation in Pregnancy on Bone Mineralization in Offspring Until Age 6 Years. JAMA Pediatrics, 2020, 174, 419.	6.2	51
9	Identification of new sensitive biomarkers for the in vivo response to interferonâ€Î² treatment in multiple sclerosis using DNAâ€array evaluation. European Journal of Neurology, 2009, 16, 1291-1298.	3.3	50
10	Disease protection and interleukinâ€10 induction by endogenous interferonâ€Î² in multiple sclerosis?. European Journal of Neurology, 2011, 18, 266-272.	3.3	40
11	Breakthrough disease during interferon-Î² therapy in MS. Neurology, 2010, 74, 1455-1462.	1.1	34
12	FOXP3, CBLBandITCHgene expression and cytotoxic T lymphocyte antigen 4 expression on CD4+CD25high T cells in multiple sclerosis. Clinical and Experimental Immunology, 2012, 170, 149-155.	2.6	34
13	FDG PET Brain Imaging in Neuropsychiatric Systemic Lupus Erythematosis With Choreic Symptoms. Clinical Nuclear Medicine, 2009, 34, 122-123.	1.3	31
14	Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 179-187.	3.0	27
15	Effect of fish oil supplementation in pregnancy on bone, lean, and fat mass at six years: randomised clinical trial. BMJ: British Medical Journal, 2018, 362, k3312.	2.3	27
16	Dynamic Tâ€lymphocyte Chemokine Receptor Expression Induced by Interferonâ€beta Therapy in Multiple Sclerosis. Scandinavian Journal of Immunology, 2006, 64, 155-163.	2.7	26
17	Blood-Brain Barrier Permeability of Normal Appearing White Matter in Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2013, 8, e56375.	2.5	26
18	The impact of <scp>EndoBarrier</scp> gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 189-199.	4.4	24

#	Article	IF	Citations
19	Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Multiple Sclerosis Journal, 2011, 17, 567-577.	3.0	23
20	Biomarkers of subclinical atherosclerosis in patients with psoriasis. Scientific Reports, 2021, 11, 21438.	3.3	22
21	Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-?1b. Cytokine, 2004, 29, 24-30.	3.2	21
22	Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 305-313.	3.0	21
23	Endogenous Interferon-Î²-Inducible Gene Expression and Interferon-Î²-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis. PLoS ONE, 2015, 10, e0118830.	2.5	18
24	Neutrophil Pathways of Inflammation Characterize the Blood Transcriptomic Signature of Patients with Psoriasis and Cardiovascular Disease. International Journal of Molecular Sciences, 2021, 22, 10818.	4.1	18
25	The effect of Î²-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. Clinical Immunology, 2008, 129, 80-89.	3.2	14
26	Endogenous and Recombinant Type I Interferons and Disease Activity in Multiple Sclerosis. PLoS ONE, 2012, 7, e35927.	2.5	14
27	18F-FET-PET in Primary Hyperparathyroidism: A Pilot Study. Diagnostics, 2016, 6, 30.	2.6	10
28	11C-Choline PET/CT vs. 99mTc-MIBI/123Iodide Subtraction SPECT/CT for Preoperative Detection of Abnormal Parathyroid Glands in Primary Hyperparathyroidism: A Prospective, Single-Centre Clinical Trial in 60 Patients. Diagnostics, 2020, 10, 975.	2.6	10
29	Associations between Inhaled Corticosteroid Use in the First 6 Years of Life and Obesity-related Traits. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 642-650.	5.6	10
30	Lobar Quantification by Ventilation/Perfusion SPECT/CT in Patients with Severe Emphysema Undergoing Lung Volume Reduction with Endobronchial Valves. Respiration, 2019, 98, 230-238.	2.6	8
31	Antibiotic exposure in infancy and development of BMI and body composition in childhood. EClinicalMedicine, 2019, 17, 100209.	7.1	7
32	Association between Vascular Inflammation and Inflammation in Adipose Tissue, Spleen, and Bone Marrow in Patients with Psoriasis. Life, 2021, 11, 305.	2.4	7
33	Multiscale Biology of Cardiovascular Risk in Psoriasis: Protocol for a Case-Control Study. JMIR Research Protocols, 2021, 10, e28669.	1.0	7
34	Statin Therapy and Vascular Inflammation Detected by Positron Emission Tomography/Computed Tomography in Patients with Psoriasis. Acta Dermato-Venereologica, 2021, 101, adv00406.	1.3	7
35	High-dose vitamin D supplementation in pregnancy and 25(OH)D sufficiency in childhood reduce the risk of fractures and improve bone mineralization in childhood: Follow-up of a randomized clinical trial. EClinicalMedicine, 2022, 43, 101254.	7.1	7
36	Predictors of Improvement in Quality of Life When Treating Hypothyroidism. Journal of Thyroid Research, 2021, 2021, 1-7.	1.3	6

#	Article	IF	Citations
37	Preoperative imaging in primary hyperparathyroidism: Are ¹¹Câ€Choline PET/CT and ^{99m}Tcâ€MIBI/¹²³Iodide subtraction SPECT/CT interchangeable or do they supplement each other?. Clinical Endocrinology, 2022, 97, 258-267.	2.4	6
38	Locating hyperfunctioning parathyroid glands using 11C-Choline PET/CT: an inter- and intra-observer variation study. European Journal of Hybrid Imaging, 2021, 5, 13.	1.5	5
39	Height and bone mineral content after inhaled corticosteroid use in the first 6 years of life. Thorax, 2022, 77, 745-751.	5.6	4
40	Added Value of Subtraction SPECT/CT in Dual-Isotope Parathyroid Scintigraphy. Diagnostics, 2020, 10, 639.	2.6	3
41	Changes in quality of life 6 months after parathyroidectomy for primary hyperparathyroidism. Endocrine Connections, 2022, 11, .	1.9	3
42	F.27. Gene Expression Analysis of Inteferon-beta and Glatiramer Acetate in Multiple Sclerosis. Clinical Immunology, 2008, 127, S51-S52.	3.2	0
43	F.61. Antigen-presenting Cell and T Cell Activation in Patients with Relapsing Remitting Multiple Sclerosis Studied by Flow Cytometry and RT-PCR. Clinical Immunology, 2009, 131, S110-S111.	3.2	0
44	F.73. Expression Profiling of Blood Mononuclear Cells from Patients with Multiple Sclerosis Identifies Differentially Expressed miRNAs and Their mRNA Targets. Clinical Immunology, 2009, 131, S113.	3.2	0